T Cell Nouveau

We are a clinical stage biopharmaceutical company aspiring to cure solid tumors with our novel TCR like CAR-T cell therapies that enhances the immune system with state of the art technology originated in prof. Hiroshi Shiku laboratory at Mie University. We strongly believe that our uniquie TCR like CAR T-cell therapy is a quantum leap toward curing solid tumors, uncovered by modern CAR/TCR-T cell therapies. Our proprietary TCR like CAR antibody is highly specific against target antigens (MAGEA4 and PRAME) in peptide-MHC complexes. Moreover our proprietary signal domain constructs help to activate, maintain and prolong T cell effect in immunosuppressive tumor microenvironment. We are proudly delivering this unique technology from prof. Hiroshi Shiku laboratory at Mie University to global medical practice. Our Mission: Lead to common CAR-T cell therapy for common cancers and common people Our Values: Bring value to the current and contribute to the next academic innovation Meet expectations of medical practitioners for innovation Always think of patients demanding such innovation